Introduction
A key focus in evaluation of treatments is to have an accurate way of measuring outcomes. Survival and time to cancer progression are common primary outcomes in oncology. However, there is increased recognition of the importance of measuring what were previously regarded as softer outcomes, such as health-related quality of life (HRQL) using patientreported outcome measures (PROMs) [1] . The number of PROMs available has grown exponentially and now there are numerous questionnaires available for assessing a multitude of domains in patients with cancer [2] . This makes it difficult to decide which PROM to use in each population. When deciding, there are a number of issues to consider: does the PROM measure what it is meant to be measuring (validity), does it do so the same way each time (reliability), and does it detect real differences or changes (sensitivity). Systematic reviews of studies that report on these measurement properties (also known as psychometric) are useful for selecting the best PROMs for a specific purpose [3] . A critical appraisal checklist to improve the selection of healthmeasurement instruments has been recommended: COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN). The checklist provides clear assessment criteria and standards, so that the methodological quality of studies that report and evaluate the psychometric properties of PROMs can be assessed as part of a review process [3, 4] . This methodology is preferred over traditional evidence-based reviews, as the focus is not the evaluation of data provided by, or outcomes of PROMs, but the methodological quality of studies that report the psychometric properties of PROMs.
Bladder cancer (BC) is the ninth most common cancer worldwide and one of the most expensive malignancies to manage [5, 6] . Treatment of and morbidity from nonmuscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC) markedly differ [7, 8] , and contribute to differences in patient HRQL [9] . Treatment choice will depend on the stage of the cancer, recommendations by clinicians, and patient preferences. This should be informed not only by survival rates but also HRQL outcomes. A review and meta-analysis of HRQL outcomes after radical cystectomy, where a variety of generic, cancer and BC-specific PROMs measuring HRQL were employed, found mostly low-powered studies finding similarities in HRQL between different types of diversions [10] . Comparisons with the general population showed not only poorer urinary and sexual functioning in patients after cystectomy, but also deficits in social interactions, physical activity, and emotional function. Although HRQL improved in the year after surgery, evidence was mixed about longer term outcomes [10] . HRQL in patients with NMIBC has been less well researched, possibly leading to the impression that there are few differences between the HRQL of patients with NMIBC and the general population [8] . However, a recent study developed a conceptual framework for patient-reported outcomes (PROs) in NMIBC derived from the literature, patients, and clinicians. This identified concerns about symptoms, treatment side-effects, functional problems, and experiences of care. Some of these were related to more contemporary treatments and were not included in current PROMs [11] .
The heterogeneity of BC and its treatments make choosing a PROM to assess HRQL challenging [9] . Accurate measurement of HRQL in BC can only be achieved if the PROM chosen is 'fit for purpose' (i.e. psychometrically sound) and applied to the correct population. If the PROMs used are not 'fit for purpose ' or are inappropriate for the patient group being studied, optimum levels of useful and informative HRQL data will not be gained from research. At worst, the data reported may be misleading or unhelpful. To date, a systematic review has not been undertaken to establish the psychometric properties of PROMs used in BC. Here we undertake a systematic review, using the COSMIN criteria. This will assess the quality of studies that report the psychometric properties of PROMs used with people with BC, determine the psychometric quality of these PROMS and identify the most promising generic, cancergeneric and BC-specific PROMs.
Materials and Methods
Methods were informed by the University of York, Centre for Reviews and Dissemination guidance for undertaking systematic reviews and were published on their international database of prospectively registered systematic reviews, PROSPERO (reference CRD42016051974). The COSMIN approach was employed [3, 4] . Guidance can be found at the COSMIN website (http://www.cosmin.nl/). The checklist has been used in other systematic reviews of oncological HRQL instruments [12, 13] and was suggested in a non-systematic review of BC HRQL research as a way to evaluate PROMs [9] . For the purposes of reporting, instruments/measures to record HRQL will be referred to as PROMs. All stages of the process following the original electronic search were undertaken by two of the research team (S.J.M., P.W.), working independently of each other and then comparing outcomes at each stage of the process. Disagreements were resolved by discussion.
Search Strategy
An electronic search of databases was carried out to identify publications evaluating psychometric properties of PROMs used in BC research. Searches were run in MEDLINE, EMBASE (both via OvidSP), CINAHL, PsycINFO, PubMed, The Cochrane Library, and Web of Science. Terms were agreed by the research team, appropriately modified for each database and limited to English language articles published between January 1990 and Current. Specific publication types were excluded from the search strategy, such as editorials and case reports, as per the search protocol developed by Terwee et al. [14] . A combination of Medical Subject Headings (MeSH) and free-text terms was used. Three groups of terms were generated describing: (i) the population; (ii) questionnaires, surveys and PROMs; and (iii) psychometric properties. Terms within each group were combined with the Boolean operator 'AND'. Searches were run in November 2016, with an updated search in September 2017. The updated search included the names of PROMs found from the initial search. Reference lists of pertinent review articles identified in the literature search were checked for relevant articles, as was conference proceedings from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and International Society for Quality Of Life Research (ISOQOL) [14] . See Data S1 for an example of one database search strategy.
Study Selection Criteria
Inclusion criteria were English language, original studies that assessed patients with BC using a questionnaire or PROM to measure HRQL, where the study was a validation study or evaluated one or more psychometric properties of the questionnaire or PROM. Excluded were studies where the patient cohort included individuals aged <18 years, where patients had bladder problems but not BC, where patients were diagnosed with another cancer (not BC), where the PROM or questionnaire was administered by interview or by proxy, and where the PROM was a clinician-assessed instrument. Review articles, meeting abstracts, interviews, conference abstracts, editorials, and commentaries were also excluded.
Pilot testing of these criteria was undertaken to check for consensus. Testing consisted of two exercises where the reviewers (S.J.M., P.W.) independently used the inclusion and exclusion criteria to select or reject a subsample of titles and abstracts (200 in total). Following the first exercise, results were compared and interpretation of the criteria was discussed. Discrepancies were resolved through discussion. Discussions focussed on the different types of urinary diversion that may be included in BC HRQL research. Consensus was reached following the second phase of pilot testing.
Full-text papers were retrieved for titles and abstracts that either appeared to meet inclusion criteria, or where uncertainty existed. These papers were further scrutinised independently by both reviewers to identify the final list included in the review.
Data Extraction
The following data were extracted from each paper: PROM(s) used, constructs measured, content of the PROM and number of items/domains, psychometric information, administration method, study setting, study population, number of patients, patient demographics, response rate, country, and language. Data required to complete the COSMIN checklist assessment were also extracted.
Appraising Methodological Quality
The 4-point COSMIN checklist was used to evaluate the methodological quality of studies, this evaluation is important as low-quality studies are considered to have a high risk of biased results. The checklist consists of nine measurement properties, each with their own quality criteria, which form three domains ('reliability', 'validity', 'responsiveness'). Three measurement properties are part of the reliability domain: 'internal consistency', 'reliability', and 'measurement error'. Five measurement properties comprise the validity domain:
'content validity', 'structural validity', 'hypothesis testing', 'cross-cultural validity', and 'criterion validity'. Responsiveness is a separate domain. An explanation of what each of the measurement properties are and COSMIN standards for reporting each measurement property is provided in Table 1 .
Each eligible study was rated for measurement properties as 'excellent', 'good', 'fair' or 'poor'. Checklist criteria are used to assess how well studies report each measurement property and whether they adhere to the COSMIN standards, e.g., providing evidence of adequate sample size, a priori hypotheses or how missing values were managed. An overall score is determined by taking the lowest rating gained on any of the checklist criteria for the evaluated measurement property: 'the worst score counts' [4] .
Reporting of Psychometric Results
The psychometric results reported in the studies were described and categorised into the nine COSMIN measurement properties. Quality criteria proposed by Terwee et al. [15] for health-status questionnaires was used to determine whether the results for each measurement property were 'positive', 'negative' or 'indeterminate'. An example of these criteria is that if a study reported a Cronbach's a of <0.70 for a PROM, the internal consistency for that study would be considered a negative result.
Levels of Evidence Appraisal
A levels-of-evidence appraisal was undertaken to determine the overall quality of each measurement property, established in the different studies. The appraisal produced a final rating for each PROM for each of the measurement properties. All available information was synthesised, combining the results of the different studies for each PROM. PROMs were rated based on COSMIN checklist scores (reflecting the methodological quality of the studies), reported psychometric evidence, and quality of the evidence (whether results were positive, negative or indeterminate), the consistency of results between studies, and level of evidence. The levels of evidence rating could be 'strong' (+++ or ÀÀÀ), 'moderate' (++ or ÀÀ), 'limited' (+ or À), 'conflicting' (+/À), or 'unknown' (?). For example, if two studies reported a Cronbach's a of <0.70 for a PROM, but had both scored 'Good' on the COSMIN checklist for internal consistency, the rating would be 'ÀÀÀ', meaning there is strong evidence (multiple studies of good methodological quality) for low levels of internal consistency. However, if there was one study reporting a Cronbach's a of >0.70 which scored 'Good' on the COSMIN checklist, the rating of that PROM for internal consistency would be '++', meaning there is moderate evidence in a study of good methodological quality. When there are only studies of poor methodological quality, an unknown rating is given. Levelsof-evidence criteria are presented in Table 2 [14] . 
Results
The initial search produced 4663 results. After removal of duplicates and screening titles and abstracts, 280 full texts were agreed for further examination, of which 19 met the inclusion criteria. Three articles were included from hand-searching the reference sections of review articles and one article was included as a result of the updated search (Fig. 1) . No results were found from hand-searching ISPOR or ISOQOL conference proceedings. Overall, 23 studies, reporting PROMs in 3568 patients, were evaluated using the COSMIN checklist. An overview of studies and PROMs are presented in Table 3 [ and Table 4 [33] and EORTC QLQ-NMIBC24 [19, 34] ). Four ad hoc MIBC PROMs were identified, which were developed specifically for the reporting study [35] [36] [37] [38] . The BCI was the most frequently evaluated PROM (six studies). None of the PROMs were evaluated for all nine COSMIN measurement properties. Table 5 presents COSMIN checklist scores, assessing methodological quality of studies that reported COSMIN measurement properties for PROMs. The most frequently reported properties were internal consistency (18 studies) and hypothesis testing (15 studies). Criterion validity was not reported in any study due to lack of a 'gold standard', according to the COSMIN definition. Studies reporting on the BCI and FACT-VCI provided the most detail and these PROMs could be evaluated on the most COSMIN measurement properties (seven properties).
Methodological Quality
The best performing property was content validity, with six of the seven reporting studies receiving a score of 'excellent'. None of the other properties were given this quality rating due to the COSMIN rule of 'worst score counts'. For example, any study not reporting quantity of missing data or how missing values were managed could not receive an excellent rating on any property that included missing values as part of the assessment. The property with the worst performance was cross-cultural validity, where all six studies scored 'poor' because factor analysis was not undertaken or the sample size was inadequate.
Psychometric Properties
An overview of the psychometric properties for all PROMs is presented in Table S1 . When reported, response rates were between 45% and 98%, although many studies did not report response rates or percentage of missing items. Internal consistency was usually presented as Cronbach's a, although one study reported an item-biased method but did not present results [36] . Cronbach's a for scales and domains were not always presented as expected. For example, a study evaluating the BCI combined the urinary, bowel and sexual function items and urinary, bowel and sexual bother items; creating two new scales for which Cronbach's a was calculated [24] instead of reporting on the scales and domains defined in the original BCI validation work [22, 23] . Testretest reliability was the only type of reliability reported by studies; with many reporting Pearson's or Spearman's correlations. Intraclass correlation (ICC) or j scores were less frequently reported when reporting test-retest reliability and some studies did not explicitly report the test carried out. Content validity was usually undertaken using a combination of literature searching, a working group of clinicians and patients, and cognitive or pilot testing of items. Structural validity was assessed by either exploratory or confirmatory factor analysis. Rasch analysis was less common (two studies [32, 36] ). Responsiveness was reported in four studies, with one study reporting effect sizes. Although aspects of hypothesis testing were presented in studies (internal relationships and correlations with other instruments) because many findings were not hypothesised a priori, these studies were considered 'indeterminate'. Table 6 presents the levels of evidence for PROMs. All PROMs had at least one negative or unknown rating for COSMIN measurement properties. Despite being the most evaluated PROM, the BCI was rated negative for the most measurement properties; with reliability and hypothesis testing both rated as moderate negative.
Levels of Evidence
Six PROMs received strong positive ratings for content validity. FACT-VCI was rated as unknown because the Cookson et al. [30] paper did not assess whether all items were relevant for the study population.
Structural validity was evaluated in eight PROMs. IONB-PRO and CAVICAVENMI received positive ratings. FACT-VCI received a moderate negative rating, as factors generated from the factor analysis of postoperative data did not explain >50% of the variance [29] . This study also presented factor analysis based on preoperative data, which was not considered appropriate as FACT-VCI is designed for use with patients who have undergone cystectomy. Five PROMs were rated unknown as the COSMIN checklist deemed the studies reporting on these PROMs to be of poor methodological quality due to inadequate sample sizes. [ Internal consistency was evaluated in eleven PROMs. The BCI and FACT-VCI were rated moderate positive. Four PROMs and three ad hoc PROMs were rated unknown, as the reporting studies were deemed to be of poor methodological quality because factor analysis had not been performed or the sample size for the analysis was too small.
Three PROMs measured test-retest reliability. The BCI was rated moderate negative as some Pearson's r figures were <0.80. CAVICAVENMI was rated unknown as the study scored poor on the COSMIN checklist for methodological quality [33] . Small sample sizes accounted for poor COSMIN checklist scores.
The IONB-PRO, the only PROM for which measurement error was reported, received an unknown rating as the study calculated the standard error measurement based on Cronbach's a [32] .
In all, 10 PROMs were evaluated for hypothesis testing. The FACT-VCI and EORTC QLQ-NMIBC24, were rated moderate positive. The BCI, FACT-Bl, EQ-5D and SF-36 received negative ratings as <75% of the a priori hypotheses were met and correlations with related constructs were lower than with unrelated ones. EORTC QLQ-C30 was rated unknown, as it was difficult to establish which constructs were similar between the PROM and comparator PROMs.
Responsiveness was evaluated in four PROMs. The BCI was rated unknown as effect sizes were reported rather than correlations or area-under-curve, as required by COSMIN.
The EORTC QLQ-NMIBC24 was moderate negative, as <75% of the results were in accordance with the stated hypotheses.
Five PROMs were evaluated for cross-cultural validity and received unknown ratings.
Discussion
The aim of the present review was to provide robust information on the psychometric properties of PROMs used with BC cohorts, to aid selection of the most appropriate PROMs for HRQL assessment. In all, 23 studies were identified that reported measurement properties of 15 PROMs used with patients with BC over the last 27 years. None of the reviewed studies that reported psychometric properties of PROMs met all COSMIN criteria standards for methodological quality. Only two measures are applicable to all BC-specific groups. Therefore, clinicians and researchers will have to choose the 'best fit' to serve their assessment objective. This may result in using a combination of generic, cancer-generic and BC-specific PROMs that reach the highest COSMIN standards.
Three generic PROMs were identified in the review, all had limited psychometric properties reported in studies; the EQ-5D, SF-36, and WHOQOL-BREF [16] [17] [18] . All three generic PROMs are established internationally with multiple non-BC studies contributing normative and psychometric properties data. Consequently, they are accepted as being valid, reliable, sensitive, and applicable to a wide range of health problems Table 4 Overview of the PROMs that were evaluated.
Name of PROM Content
Generic EQ-5D 5 items: mobility, self-care, usual activities, pain, anxiety and depression, plus a visual analogue scale SF- 36 36 items overall, mental component scale and physical component scale WHOQOL-BREF 26 items; one from each of the 24 facets of WHOQOL100 plus 2 items from quality of life and general health items. Scales were physical health, psychological health, social relationships, and environment Cancer generic EORTC QLQ-C30 30 items. 9 scales. Functional scales: physical, role, emotional, cognitive, social, and global health status/quality of life. Symptom scales/items: fatigue, pain, and nausea and vomiting. Single items: dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties Bladder cancer BCI 36 items. 3 domains: urinary (14 items), bowel (10 items), and sexual (12 items). 6 subscales as each domain has a function and bother subscale FACT-Bl 13 items specific to bladder cancer plus 27 item FACT-G that comprises 4 scales; functional, social/family and physical wellbeing scales (7 items), emotional wellbeing scale (6 items) MIBC FACT-VCI 17 items specific to radical cystectomy patients, plus 27 item FACT-G that comprises 4 scales; functional, social/family and physical wellbeing scales (7 items), emotional wellbeing scale (6 items) IONB-PRO Relational, fatigue, and emotional scales. Analysis from research produced several other scales EORTC QLQ-BLM30 30 items. 6 scales: urinary symptoms/problems, urostomy problems, future perspective, bloating and flatulence, body image and sexuality, plus single item about catheter use Caffo et al. [35] Ad hoc PROM. 40 items for cystectomy version, 41 for conservative treatment version. Items about physical wellbeing, pain, bowel function, urinary function, sexual function, daily physical activities, relational and recreational activities, stoma, and general items Bjerre et al. [36] Ad hoc PROM. 211 items including items about urine leakage, diarrhoea, and skin complications Hart et al. [37] Ad hoc PROM. About 105 items on emotional distress, quality of life (global), sexual dissatisfaction, body image, urinary diversion problems, sexual function, physical symptomology, daily living activities Henningsohn et al. [38] Ad hoc PROM. 137 items for patients, 125 for controls about urinary symptoms, bowel, and sexual dysfunction NMIBC EORTC QLQ-NMIBC24 24 items. 6 scales: urinary symptoms, malaise, future worries, bloating and flatulence, sexual function, male sexual problems, plus 5 single items; intravesical treatment issues, sexual intimacy, risk of contaminating partner, sexual enjoyment and female sexual problems CAVICAVENMI 21 items. [39] . However, they may lack sensitivity in measuring cancer and BC-specific issues, which is where more specialised PROMs, have a part to play. If being used alongside other more specific PROMs, clinicians and researchers may want to consider the following as part of their decision-making process: the scope of the generic PROM, the number of items included, ease of administration, and permissions and costs.
Cancer-generic PROMs, such as the EORTC QLQ-C30 and FACT -General (FACT-G), provide information about patient experiences of general symptoms, such as nausea, pain and fatigue, and the impact of cancer on a patient's daily life, emotional health, and relationships. They can be used to compare the HRQL of patients with BC with other cancer populations. Although used as a stand-alone cancer-generic PROM in BC research, FACT-G was not evaluated separately in the present review due to its inclusion as part of the FACT-Bl and FACT-VCI.
As with generic PROMs, psychometric evaluation of the EORTC QLQ-C30 was not the focal point of studies included in the present review and thus very few psychometric properties were reported. During EORTC QLQ-C30 development, the PROM was psychometrically evaluated in a culturally diverse sample of patients with lung cancer [40] and by 2008, EORTC published reference data for a variety of cancer groups (but not for patients with BC) [41] . Despite this, EORTC QLQ-C30 is used in BC HRQL research.
BC-specific PROMs focus on commonly reported BC problems such as with urinary, bowel and sexual function. Findings reported using these more specific PROMs may inform BC treatment regimens, policy and patient support. In the main, BC-specific PROMs have been developed more recently than their generic and cancer-generic counterparts and therefore have not been as widely used in research. There were 11 BC-specific PROMs reviewed, of variable quality. On choosing which PROM to use, consideration should be given to how well it performed in the COSMIN review and the population of patients with BC being assessed.
If the target population includes the entire BC spectrum, then the choice of BC-specific PROM must have been designed for this purpose. Only two PROMs fit this brief, the BCI and FACT-Bl. Our present review found more support for the BCI, as it was more frequently evaluated in research and scored more favourably using COSMIN. However, the BCI is not without flaw, as evidence has suggested it may be difficult to interpret in circumstances where function and bother scores are different for a domain, under which circumstances researchers must choose whether HRQL should be determined by symptoms (function) or importance of symptoms to the patient (bother) [42] . Consequently, it was recommended that a generic or cancergeneric PROM be administered alongside the BCI [42] . In comparison, FACT-Bl scored poorly on the COSMIN checklist for all reported properties. However, a recent overview paper of Table 6 Overall levels of evidence per measurement property and PROM. BC PROMs suggests that the FACT-Bl performs better than indicated in the present review. The authors state each new Functional Assessment of Chronic Illness Therapy (FACIT) scale undergoes an assessment of test-retest reliability, responsiveness, and convergent and divergent validity with 50 patients [42] (confirmed by personal correspondence with FACIT, by S.J.M. on 14/09/2017). These psychometric data are neither published nor available within the public domain, meaning a complete COSMIN assessment cannot be undertaken, and therefore recommendation for use is not possible.
Seven MIBC-specific PROMs were reported. The FACT-VCI was the most evaluated in studies and had the most positive COSMIN ratings. It is used in HRQL studies comparing types of diversion, but is unsuitable to use with conservative treatment patients. Comparatively, the EORTC QLQ-BLM30 was assessed for two measurement properties only, but can compare radical and conservative treatment-related HRQL. Although only evaluated by one study, the IONB-PRO scored well using the COSMIN checklist and appears to be a viable tool to administer to MIBC patients with neobladders. Four studies reported psychometric properties for a number of unnamed, ad hoc PROMs [35] [36] [37] [38] , with no traceable evidence of further use.
Two PROMs were identified that measure HRQL in patients with NMIBC; both performing well when assessed using COSMIN. Although the case could be made to use either the EORTC QLQ-NMIBC24 or CAVICAVENMI in research, the EORTC QLQ-NMIBC24 has been evaluated more in research and can be used alongside EORTC QLQ-C30. However, should clinicians and researchers prefer to use a PROM that includes a combination of cancer-generic and BC-specific items that comprises fewer items, they may wish to use CAVICAVENMI over the EORTC QLQ-BLM30 combined with EORTC QLQ-C30. Findings are described in Table 7 .
Strengths and Limitations
Although a strength of the present research is that methodological quality was assessed using the robust COSMIN checklist, carrying out the appraisal provided challenges. Many studies were not written with COSMIN criteria in mind, meaning interpretation of which COSMIN measurement properties were being assessed was sometimes difficult. For example, Blazeby et al. [19] employed multi-trait scaling when evaluating the structural validity of the EORTC QLQ-NMIBC24. Multi-trait scaling is not referred to in the COSMIN guidance. Advice from COSMIN (S.J.M. personal communication with Terwee 08/05/2017) stated that this method was not appropriate to assess structural validity. The complexity of applying the checklist appears to be acknowledged by COSMIN as the checklist is under review [43] and their website has a frequently asked question (FAQ) section, regarding which measurement properties should be assessed when terminology other than that used by COSMIN is reported. Studies that received a negative or unknown rating, published following the publication of the COSMIN guidance, may have received a more favourable COSMIN rating if their guidelines had been taken into account when reporting the psychometric properties of PROMs.
Recommendations
The emergence of new questionnaires, currently published as conference abstracts only [44] and the identification of the four [13, 45] , the present review identified fewer PROM-validation studies reporting an array of psychometric data. Unlike in other cancer populations, the psychometric properties of generic and general cancer PROMs are less well understood in BC populations. There would be a benefit in pooling data from studies that have used generic, cancer-generic and BC-specific PROMs to facilitate the undertaking of a more detailed psychometric analysis. This would enable organisations such as the EORTC to determine reference values for patients with BC and provide research teams with more information when choosing PROM(s) for HRQL research.
Any future psychometric evaluation of generic, cancer-generic and BC-specific PROMs should be reported and published, ideally using the COSMIN guidelines, so that it can be determined how useful these PROMs are with their intended BC populations.
Future HRQL research should implement the recommendation from previous research that BC-specific PROMs be used alongside cancer-generic PROMs in order to gain comprehensive information. Furthermore, it is recommended that generic PROMs should also be administered alongside cancer-generic and BC-specific PROMs to provide a robust picture of HRQL.
outcome (measure); SF-36, 36-item short-form health survey; WHOQOL-BREF, World Health Organisation Quality of Life.
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